期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

紫杉醇耐药与β微管蛋白Ⅲ研究进展 被引量：5

Research development on drug resistance of taxol and βtubulin Ⅲ
原文传递
导出
摘要 紫杉醇依赖于促进微管聚合，抑制微管解聚，诱导肿瘤细胞凋亡，但肿瘤细胞对紫杉醇的耐药性是限制其临床应用的重要因素。一些基础、临床研究均证实β微管蛋白Ⅲ高表达与紫杉醇耐药、预后不良密切相关。 The taxol′ s effect of inducing apoptosis is mainly related to its ability to promote tubulin polymerization and prevent tubulin chain depolarization. Drug resistance is the main restriction factor for clinical usage of taxol. Some basic and clinical studies support that poor response to taxol and poor prognosis are related to overexpression of β tubulin Ⅲ.
作者 杨全良(综述) 蒋华蔚(综述) 凌扬(审校)
机构地区 苏州大学附属常州肿瘤医院内科
出处 《肿瘤研究与临床》 CAS 2011年第2期137-139,共3页 Cancer Research and Clinic
关键词 微管蛋白 紫杉醇 抗药性 肿瘤 Tubulin Taxol Drug resistance, neoplasms
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献21

  • 1EI-Kareh AW, Labes RE, Secomb TW. Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drags. AAPS J, 2008, 10: 15-34.
  • 2Hammond JW, Cai D, Verhey KI. Tubulin modifications and their cellular functions. Curr Opin Cell Biol, 2008, 20: 71-76.
  • 3Wade RH. Microtubules: an overview. Methods Mol Med, 2007, 137: 1-16.
  • 4Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer, 2010, 10: 194-204.
  • 5Mozzetti S, Ferlini C, Concolino P, et al. Class Ⅲ β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res, 2005, 11: 298-305.
  • 6Umezu T, Shibata K, Kajiyama H, et al. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class Ⅲ beta-tubulin. Int J Gynecol Pathol, 2008, 27: 207-212.
  • 7Ferrandina G, Zannoni GF, Martinelli E, et al. Class Ⅲ β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res, 2006, 12: 2774-2779.
  • 8Aoki D, Oda Y, Hattori S, et al. Overexpression of class Ⅲ beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res, 2009, 15: 1473-1480.
  • 9Wehbe H, Kearney CM, Pinncy KG, et al. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tuhulin isotype expression. Anticancer Res, 2005, 25: 3865-3870.
  • 10Kavallaris M, Burkhart CA, Horwitz SB, et al. Antisense oligonucleotides to class Ⅲ beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer, 1999, 80: 1020-1025.

二级参考文献6

  • 1Sere P,Mackey J,Isaac S,et al.Class Ⅲ beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel[J].Mol Cancer Ther,2005,4 (12):2001-2007.
  • 2Sevc P,Isaac S,Tredan O,et al.Expression of class Ⅲ {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy[J].Clin Cancer Res,2005,11 (15):5481-5486.
  • 3Kelley M J,Li S,Harpole DH.Genetic analysis of the beta-tubulin gene,TUBB,in non-small-cell lung cancer[J].J Natl Cancer Inst,2001,93(24):1886-1888.
  • 4Mozzetti S,Ferlini C,Concolino P,et al.Class Ⅲ beta-tubulin over-expression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients[J].Clin Cancer Res,2005,11(1):298-305.
  • 5Rosell R,Scagliotti G,Danenberg KD,et al.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer[J].Oncogene,2003,22 (23):3548-3553.
  • 6Paradiso A,Mangia A,Chiriatti A,et al.Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer[J].Ann Oncol,2005,16(Suppl 4):14-19.

共引文献13

同被引文献56

引证文献5

二级引证文献10

肿瘤研究与临床
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部